Search Results for "rapid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rapid. Results 91 to 100 of 109 total matches.
Two Vonoprazan Combinations (Voquezna) for H. pylori
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
. Vonoprazan is more rapidly
absorbed, achieves a higher intragastric pH, and has
a longer half-life than ...
The FDA has approved vonoprazan, a potassium-competitive
acid blocker, copackaged with amoxicillin
(Voquezna Dual Pak – Phathom) and with amoxicillin
and clarithromycin (Voquezna Triple Pak) for
treatment of Helicobacter pylori infection in adults.
Vonoprazan is the first potassium-competitive acid
blocker to be approved in the US. It has been available
in Japan for treatment of various acid-related
disorders since 2014. Vonoprazan is not available
alone in the US.
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
be rapidly and completely
reversed by protamine, it is not renally eliminated and
may be safer in patients ...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023 (Issue 1691)
evidence for claims that it acts more rapidly than SSRIs. Vilazodone has an adverse effect profile similar ...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200 doi:10.58347/tml.2023.1691a | Show Introduction Hide Introduction
Drugs for ADHD
The Medical Letter on Drugs and Therapeutics • Sep 01, 2025 (Issue 1736)
in children and adults.
Short-acting methylphenidate formulations (Ritalin, and
others) are rapidly absorbed ...
Attention-deficit/hyperactivity disorder (ADHD) is a
common chronic neurodevelopmental disorder often
diagnosed in school-age children that frequently
persists into adulthood.Pharmacologic treatment
of ADHD has been associated with reduced risks of
substance abuse, criminal behavior, unintentional
injuries, serious traffic accidents, and all-cause
mortality. Drugs approved by the FDA for treatment
of ADHD are listed in Table 1.
Med Lett Drugs Ther. 2025 Sep 1;67(1736):137-44 doi:10.58347/tml.2025.1736a | Show Introduction Hide Introduction
Drugs for Hypothyroidism
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
rather than the
4- to 6-week intervals recommended for LT4. The
rapid absorption of LT3 combined ...
Primary hypothyroidism is usually the result of
Hashimoto's (autoimmune) thyroiditis, thyroidectomy,
or radioactive iodine therapy. Treatment of
hypothyroidism with replacement doses of thyroid
hormone is usually lifelong. Levothyroxine (LT4;
synthetic thyroxine; Synthroid, and others) is the drug
of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9 doi:10.58347/tml.2023.1670a | Show Introduction Hide Introduction
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024 (Issue 1716)
-acting beta2-
agonists (SABAs) albuterol and levalbuterol are used
as needed for rapid relief of asthma ...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations in the
emergency department is not discussed here.
Med Lett Drugs Ther. 2024 Nov 25;66(1716):185-92 doi:10.58347/tml.2024.1716a | Show Introduction Hide Introduction
Treatment of Clostridioides difficile Infection
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
with Clostridium difficile
(RAPID): a randomised placebo controlled trial. Gut 2019; 68:1224.
22. E van Nood et ...
Clostridioides (formerly Clostridium) difficile infection
(CDI) is the most common infectious cause of
healthcare-associated diarrhea in adults. Guidelines
on management of CDI have recently been updated.
Drugs for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025 (Issue 1719)
is characterized by a rapid decrease in central
visual acuity due to development of leaky new blood
vessels ...
Age-related macular degeneration (AMD) has two
major forms: dry or non-neovascular (~90% of
patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5 doi:10.58347/tml.2025.1719a | Show Introduction Hide Introduction
Drugs for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • May 02, 2022 (Issue 1649)
rapidly relieve symptoms, but
they do not slow disease progression.
The 5α-reductase inhibitors ...
About 60% of men ≥60 years old have clinically
relevant prostatic enlargement due to benign prostatic
hyperplasia (BPH). The goals of treatment are to
decrease lower urinary tract symptoms and to prevent
disease progression and complications such as acute
urinary retention. The American Urologic Association's
guidelines for treatment of BPH were recently updated.
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
effect. Second-generation antipsychotic
drugs (see Tables 2 and 3), which act more rapidly,
can be used ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction